TY - JOUR
T1 - Prognostic value of thallium-201 single-photon emission computed tomography for patients with multivessel coronary artery disease after revascularization (the Emory Angioplasty versus Surgery Trial [EAST])
AU - Alazraki, Naomi P.
AU - Krawczynska, Elizabeth G.
AU - Kosinski, Andrzej S.
AU - DePuey, E. Gordon
AU - Ziffer, Jack A.
AU - Taylor, Andrew T.
AU - Pettigrew, Roderic I.
AU - Vansant, Johnathan P.
AU - Shaw, Leslee J.
AU - Weintraub, William S.
AU - King, Spencer B.
N1 - Funding Information:
This study was supported by Grant RO1 HL 33965 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 1999/12/15
Y1 - 1999/12/15
N2 - The aim of this study was to investigate the relation between reversible thallium single-photon emission computed tomography (SPECT) myocardial perfusion defects at 1-year after revascularization and quantitative indexes in Emory Angioplasty versus Surgery Trial (EAST) and outcomes 3 years after revascularization in 336 patients. EAST was a randomized controlled trial assessing cardiac outcomes for angioplasty versus bypass surgery for patients with multivessel coronary artery disease. During this prospective trial, a substudy included the evaluation of the prognostic value of reversible defects on quantitative thallium SPECT. At 1-year after revascularization, 336 patients underwent SPECT thallium-201 stress myocardial perfusion and 3-hour delayed imaging. Subsequent events, percutaneous transluminal coronary angioplasty, coronary artery bypass graft surgery, myocardial infarction, and death, were recorded at 3 years. A stress-induced reversible thallium-201 defect was defined using a quantitative index of a reversibility score >30% and severity score >500. Reversible defects were observed more frequently in the percutaneous transluminal coronary angioplasty than in the coronary artery bypass graft surgery treatment groups (46% vs 27%, p <0.001). A total of 123 patients had stress-induced, reversible thallium defects and more events than patients with other perfusion results (freedom from all events was 81.3% vs 94% [p <0.001], and freedom from myocardial infarction and death 88.3% vs 95.5% [p = 0.031]). Quantitative thallium SPECT at 1 year after revascularization risk stratifies patients as to their likelihood of major cardiac outcomes. Copyright (C) 1999 Excerpta Medica Inc.
AB - The aim of this study was to investigate the relation between reversible thallium single-photon emission computed tomography (SPECT) myocardial perfusion defects at 1-year after revascularization and quantitative indexes in Emory Angioplasty versus Surgery Trial (EAST) and outcomes 3 years after revascularization in 336 patients. EAST was a randomized controlled trial assessing cardiac outcomes for angioplasty versus bypass surgery for patients with multivessel coronary artery disease. During this prospective trial, a substudy included the evaluation of the prognostic value of reversible defects on quantitative thallium SPECT. At 1-year after revascularization, 336 patients underwent SPECT thallium-201 stress myocardial perfusion and 3-hour delayed imaging. Subsequent events, percutaneous transluminal coronary angioplasty, coronary artery bypass graft surgery, myocardial infarction, and death, were recorded at 3 years. A stress-induced reversible thallium-201 defect was defined using a quantitative index of a reversibility score >30% and severity score >500. Reversible defects were observed more frequently in the percutaneous transluminal coronary angioplasty than in the coronary artery bypass graft surgery treatment groups (46% vs 27%, p <0.001). A total of 123 patients had stress-induced, reversible thallium defects and more events than patients with other perfusion results (freedom from all events was 81.3% vs 94% [p <0.001], and freedom from myocardial infarction and death 88.3% vs 95.5% [p = 0.031]). Quantitative thallium SPECT at 1 year after revascularization risk stratifies patients as to their likelihood of major cardiac outcomes. Copyright (C) 1999 Excerpta Medica Inc.
UR - http://www.scopus.com/inward/record.url?scp=0032739063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032739063&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(99)00578-0
DO - 10.1016/S0002-9149(99)00578-0
M3 - Article
C2 - 10606106
AN - SCOPUS:0032739063
SN - 0002-9149
VL - 84
SP - 1369
EP - 1374
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 12
ER -